SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

PTGX gets U.S. FDA approval for rusfertide in Polycythemia Vera

Protagonist Therapeutics said the U.S. FDA approved MIMRYLO (rusfertide) for Polycythemia Vera.

PTGX

Story updates

12:30:07 AM UTC
SquawkNews
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.